Adrenocorticotropic Hormone Market Size to Hit US$ US$ 1.95 Billion by 2031 | Growth Plus Reports


Newark, New Castle, USA, June 15, 2023 (GLOBE NEWSWIRE) — The market analysis of the global adrenocorticotropic hormone market was conducted by Growth Plus Reports in 2022 and was valued at US$ 1.33 billion. The market is expected to hit a revenue CAGR of 4.3% to reach US$ 1.95 billion by 2031.

The global adrenocorticotropic hormone (ACTH) market is anticipated to experience significant growth as the incidence of adrenal disorders continues to rise, and there is an increasing demand for diagnostic testing to assess adrenal function. The pituitary gland’s hormone ACTH, which controls cortisol synthesis and adrenal gland function, is essential.

Request a Free Sample PDF:


                                  Adrenocorticotropic Hormone Market Scope

Report Attribute Details
Market size value in 2022 US$ 1.33 billion
Revenue forecast in 2031 US$ 1.95 billion
Growth Rate CAGR of 4.3% from 2023 to 2031
Base Year for Estimation 2022
Forecast Period 2023-2031
Historical Year 2021
Segments Covered Source, Application, End-user, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

The market for ACTH is primarily driven by the increased frequency of adrenal illnesses such as congenital adrenal hyperplasia, Cushing’s syndrome, and adrenal insufficiency. These conditions often require diagnostic testing to evaluate the adrenal function, leading to increased demand for ACTH testing. Increased awareness about the symptoms and consequences of adrenal disorders, coupled with the implementation of screening programs, has contributed to the early detection and diagnosis of these conditions. ACTH testing is a vital component of the diagnostic process, fueling market growth.

Furthermore, technological advancements in diagnostic testing have led to the development of accurate and sensitive assays for measuring ACTH levels. Improved laboratory techniques, such as immunoassays and mass spectrometry, enhance the precision and reliability of ACTH testing, driving the market growth. The increasing healthcare expenditure across the globe has resulted in investments in advanced diagnostic technologies. Healthcare facilities are acquiring automated and efficient testing platforms for ACTH analysis, improving the accessibility and affordability of diagnostic testing.

Request for Customization –

Recent Development in the Adrenocorticotropic Hormone Market: 

  • In January 2023, an exclusive licensing deal was announced by Spruce Biosciences, Inc. and Kaken Pharmaceutical Co. Ltd. for Spruce’s product candidate, tildacerfont, to be developed and marketed in Japan for the treatment of congenital adrenal hyperplasia (CAH). Tildacerfont is a non-steroidal oral antagonist of the corticotropin-releasing factor (CRF) 1 receptor that is very powerful and selective. Spruce will get a $15 million opening payment from Kaken. They will be qualified for further payments upon meeting future research and commercial milestones, as well as tier-based double-digit royalties on net sales in Japan, per the terms of the deal.

Competitive Landscape

A list of the prominent players actively operating in the global market for adrenocorticotropic hormone includes: 

  • BCN Peptides S.A.U
  • Mallinckrodt Pharmaceuticals
  • Pfizer Inc.
  • GlaxoSmithKline plc 
  • Hikma Pharmaceuticals plc
  • Merck KGaA
  • These companies are focusing on research and development activities, collaborations with healthcare institutions, and product launches to gain a competitive advantage in the market.

Market Restraints: 

Adrenal disorders are often underdiagnosed or misdiagnosed due to their diverse clinical presentations and overlapping symptoms with other conditions. Limited awareness among healthcare professionals and challenges in accurately diagnosing adrenal disorders may hinder the market growth. The cost of diagnostic testing, including ACTH assays, can be a significant barrier, especially in resource-constrained healthcare settings. The high cost of equipment, reagents, and specialized laboratory infrastructure may limit the widespread adoption of ACTH testing.

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursements
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Natural 
    2. Synthetic
    1. Neurology
    2. Rheumatology
    3. Ophthalmology
    4. Nephrotic Syndrome
    5. Others
    1. Hospitals and Clinics
    2. Home Care
    3. Others


Buy this Premium Research Report:


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst:

Visit our report store at –

Browse more latest healthcare reports:

Glucose Elevating Agents Market by Products (Glucagon, Diazoxide), Indication (Hypoglycemia, Insulinoma), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), – Global Outlook & Forecast 2023-2031

Ergocalciferol Market by Application (Hypoparathyroidism, Rickets), Route of Administration (Oral, Injectable), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Leptin Based Therapeutics Market by Application (Obesity, Diabetes), Type (Recombinant Leptin, Leptin Receptor Agonists), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

ABCA4 Retinopathy Therapeutics Market by Drug Type (Anti-VEGF Drugs, LBS-008), Age Group (Children, Adults), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) – Global Outlook & Forecast 2023-2031

Tocolytic Agents Market by Drug Class (Magnesium Sulfate, Betamimetics), Route of Administration (Oral, Parenteral) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web:

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.